Chronic myelogenous leukemia in the chronic phase with lymph node swelling which represented extramedullary involvement composed of cells at different stages of maturation.
ABSTRACT In chronic myelogenous leukemia (CML), lymph node swelling is generally considered an early sign of blast crisis. We encountered a rare case of CML showing marked lymph node swelling, which represented extramedullary involvement composed of cells at different stages of maturation but not showing blast crisis. In 1996, a 60-year-old Japanese male was diagnosed with CML in the chronic phase, and imatinib mesylate was prescribed following interferon-alpha treatment in 2004. However, the patient chose to discontinue out patient treatment 1 year later. He was referred to our hospital because of severe fatigue in August 2006, and laboratory tests showed a WBC count of 347.9 x 10(9)/l with 6.5% blasts. On bone marrow tests, Ph chromosome presence was found in all cells examined, but there was no additional chromosomal abnormality. Cytogenetic analysis revealed that 82% of cells in on employing FISH showed BCR/ABL. The patient had swelling of the left cervical and both inguinal lymph nodes. A lymph node biopsy showed proliferation in three lineages of hematological cells at different stages of maturation. He was diagnosed with CML in the chronic phase. He was given imatinib mesylate and hydroxyurea, and achieved hematological remission. Sixteen months later, he developed blast crisis and died of cerebral hemorrhage. Such a case of extramedullary involvement composed of cells at different stages of maturation is rare, and suggests the need to biopsy extramedullary tumors in order to evaluate the clinical phase.
- SourceAvailable from: Guang Fan
British Journal of Haematology 12/2012; 161(1). DOI:10.1111/bjh.12180 · 4.96 Impact Factor
- "Due to the profound anemia with normal platelet count and no prominent leucocytosis , it would not be possible to reach the diagnosis of CML, except for the identification of BCR-ABL1 p210, which is pathogenomonic of CML (Foroni et al, 2009). Paediatric CML is a very rare disease, and involvement of extramedullary tissues, such as the LNs, is generally limited to blast crisis (Kobayashi et al, 2011). When CML enters BC, the prognosis is extremely poor, with an overall survival of 4 months for patients treated with conventional chemotherapy or interferon-a, and 7Á5 months for patients treated with imatinib (Hehlmann & Saussele, 2008). "